Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22921868 | 0.91 | TSHR (0.58) | MAPTTSHREPHX2CYP4F2CYP4A11 | |
| Cyclopropane SCHEMBL11851783 | 0.90 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL197699 | 0.89 | CYP11B1 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9236090 | 0.88 | NPC1 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9233984 | 0.87 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8895651 | 0.86 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7718832 | 0.86 | TSHR (0.48) | TSHREPHX2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL11296823 | 0.85 | SLC2A1 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23700758 | 0.85 | HDAC1 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9236137 | 0.85 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114487184-A | Method for measuring 2 beta-carbomethoxy-3 beta- (4-chlorphenyl) tropane and related substances thereof | 江苏省原子医学研究所 | 2022-05-13 | — | — | CN | claimed |
| JP-2002514161-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-0927033-A4 | — | — | 1999-07-07 | — | — | EP | claimed |
| EP-0927033-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1999-07-07 | — | — | EP | claimed |
| WO-1998000127-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1998-01-08 | — | — | WO | claimed |
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | DJ Therapeutics LLC (US) | 2025-06-24 | — | — | US | disclosed |
| CN-114487184-A | Method for measuring 2 beta-carbomethoxy-3 beta- (4-chlorphenyl) tropane and related substances thereof | 江苏省原子医学研究所 | 2022-05-13 | — | — | CN | disclosed |
| CN-114487184-A | Method for measuring 2 beta-carbomethoxy-3 beta- (4-chlorphenyl) tropane and related substances thereof | 江苏省原子医学研究所 | 2022-05-13 | — | — | CN | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| CN-112218629-A | Bexarotene derivatives and their use in the treatment of cancer | DJ疗法有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3758694-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-103384661-B | Mineralocorticoid receptor antagonists | 默沙东公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20030203934-A1 | Cocaine receptor binding ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-30 | — | — | US | disclosed |
| EP-0927033-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1999-07-07 | — | — | EP | disclosed |
| EP-0927033-A4 | — | — | 1999-07-07 | — | — | EP | disclosed |
| WO-1998000127-A1 | RETINOYLOXY(SUBSTITUTED)ALKYLENE BUTYRATES USEFUL FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | BAR-ILAN UNIVERSITY (IL) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | C3AR1, CXCR3, CCR7 | HDAC3 2064/4885HDAC4 3485/4885HDAC1 2549/4885 |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | ENPP2, XPA, CCR8 | HDAC3 3331/4885HDAC4 2601/4885HDAC1 3834/4885 |
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | CXCR3, CCR6, CCR9 | HDAC3 1961/4885HDAC4 2497/4885HDAC1 2937/4885 |
| US-20030203934-A1 | Cocaine receptor binding ligands | SLC18A2, SLC6A3, SLC18A3 | HDAC3 3222/4885HDAC4 3590/4885HDAC1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.